Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 131,856 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Nikita Shah also recently made the following trade(s):

• On Monday, August 25th, Nikita Shah sold 6,340 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.50, for a total transaction of $60,230.00.
• On Friday, August 22nd, Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72.

Amneal Pharmaceuticals Trading Up 1.0%

NASDAQ:AMRX traded up $0.12 on Friday, reaching $11.64. The stock had a trading volume of 959,349 shares, compared to its average volume of 1,688,060. The company has a 50-day moving average of $10.33 and a 200 day moving average of $8.90. The stock has a market cap of $3.66 billion, a P/E ratio of 1,165.17 and a beta of 1.21. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $12.12.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP raised its holdings in shares of Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the period. California State Teachers Retirement System grew its position in shares of Amneal Pharmaceuticals by 16.5% during the 3rd quarter. California State Teachers Retirement System now owns 150,781 shares of the company’s stock valued at $1,509,000 after buying an additional 21,324 shares during the last quarter. Two Sigma Investments LP raised its stake in Amneal Pharmaceuticals by 291.9% during the third quarter. Two Sigma Investments LP now owns 69,534 shares of the company’s stock worth $696,000 after acquiring an additional 51,789 shares during the period. Comerica Bank lifted its holdings in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Jump Financial LLC boosted its stake in Amneal Pharmaceuticals by 16.8% in the third quarter. Jump Financial LLC now owns 304,597 shares of the company’s stock valued at $3,049,000 after acquiring an additional 43,747 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on AMRX shares. Piper Sandler reiterated an “overweight” rating and set a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. JPMorgan Chase & Co. increased their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $12.50.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.